Breast cancer, Secondary cancers
Results
Phase 2
This trial looked at adding everolimus to letrozole and exemestane for breast cancer.
It was for women whose breast cancer had grown into the surrounding tissue or had spread elsewhere in the body. And whose breast cancer cells had:
receptors for oestrogen or progesterone (is hormone receptor positive)
low or no amounts of HER2 ( negative cancer)
Recruitment start: 7 March 2013
Recruitment end: 17 December 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Mark Beresford
Novartis
Last reviewed: 05 Feb 2019
CRUK internal database number: 12151
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
